Hansa Biopharma AB
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Hansa Medical AB (to 2020)
4
Ending by 2030
Jun 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 6, 2026The maintenance fee for Cysteine Protease (US 11,667,905) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,784,741 | Diagnostic method In force · From the USPTO record | In force | From the USPTO record | |
| US 8,133,483 | Method of treating or preventing a disease or condition mediated by pathogenic IgG antibodies In force · From the USPTO record | In force | From the USPTO record | |
| US 8,518,648 | Diagnostic method In force · From the USPTO record | In force | From the USPTO record | |
| US 8,889,128 | Use of the endoglycosidase endos for treating immunoglobulin G mediated diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 10,126,312 | Diagnostic method for urinary tract infection In force · From the USPTO record | In force | From the USPTO record | |
| US 9,707,279 | Treatment for IgE-mediated disease In force · From the USPTO record | In force | From the USPTO record | |
| US 9,759,720 | Diagnostic method for bacterial meningitis In force · From the USPTO record | In force | From the USPTO record | |
| US 10,973,889 | Method for improving the benefit of organ transplant In force · From the USPTO record | In force | From the USPTO record | |
| US 10,696,959 | Cysteine Protease In force · High confidence | In force | High confidence | |
| US 10,758,597 | Variant Cysteine Proteases In force · High confidence | In force | High confidence |
Also on record, not counted in the 16: 3 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 1 no status recorded